These results establish GHK-Cus superior performance compared to established cosmeceutical ingredients
Potential Benefits Joint pain and injury: used clinically for knee, shoulder, wrist, and hip conditions including arthritis, tendon injuries, cartilage damage, and general joint discomfort, via both subcutaneous and intra-articular injection protocols Musculoskeletal trauma: prescribed for fractures (including hairline fractures of the foot), wrist injuries, muscle strains, tendon damage, and soft tissue injuries to support structural and functional recovery Post-surgical recovery: used following orthopedic and other surgical procedures to support tissue repair at the operative site through angiogenesis, collagen synthesis, and inflammatory modulation Sports and exercise recovery: used by active patients experiencing slow recovery from training, muscle discomfort, and exercise-related soft tissue injuries, with the aim of shortening recovery time between sessions Gut health and systemic inflammation: investigated for gastrointestinal mucosal protection, reduction of systemic inflammatory markers, and tissue repair in patients with GI conditions or inflammatory presentations Degenerative joint conditions: prescribed for advanced degenerative joint changes and chronic pain conditions where conventional treatments have provided incomplete relief, including chronic knee and hip degeneration Skin healing and wound repair: prescribed for tissue regeneration and skin wound healing, including extended protocols for patients with significant skin healing requirements Tendon repair across multiple sites: shown in preclinical and emerging clinical research to support Achilles, patellar, rotator cuff, and deltoid tendon repair through collagen synthesis promotion and angiogenesis Anti-inflammatory effect on connective tissue: counteracts the anti-healing effects that NSAIDs and corticosteroids can impose on tendons and connective tissue, relevant for patients with prior steroid injection history Investigated for organ-protective properties in preclinical research, including liver, kidney, and cardiac tissue following injury or ischemic events Speak with a physician Interested in BPC-157
L-NAME+L-arginine treated rats had IVH size 21.421.4 (p=0.053)
Strength training and moderate cardio combine well
